Unswitch-ABL Drugs Overcome Resistance in Chronic Myeloid Leukemia

Publications

April 25, 2011

Cancer Cell, Volume 19, Issue 4, 12 April 2011, Pages 435-437

Wayne W. Chan, 4, Scott C. Wise, Michael D. Kaufman, Yu Mi Ahn, Carol L. Ensinger, Torsten Haack, Molly M. Hood, Jennifer Jones, John W. Lord, Wei Ping Lu, David Miller, William C. Patt, Bryan D. Smith, Peter A. Petillo, Thomas J. Rutkoski, Hanumaiah Telikepalli, Lakshminarayana Vogeti, Tony Yao, Lawrence Chun, Robin Clark, Peter Evangelista, L. Cristina Gavrilescu, Katherine Lazarides, Virginia M. Zaleskas, Lance J. Stewart, Richard A. Van Etten, and Daniel L. Flynn

ABSTRACT

ABL inhibitors have revolutionized the clinical management of chronic myeloid leukemia, but the BCR-ABL^T315I mutation confers resistance to currently approved drugs. Chan et al. show, in this issue of Cancer Cell, that switch-control inhibitors block BCR-ABL^T315I activity by preventing ABL from switching from the inactive to active conformation.

« Publications home page

Recent Publications
12/31/11 Predicting thesuccess of fragment screening by X-ray crystallography
12/31/11 Small molecule allosteric modulators of phosphodiesterase 4
12/31/11 Small molecule allosteric modulators of phosphodiesterase 4
10/13/11 Structural characterization of a ribose-5-phosphate isomerase B from the pathogenic fungus Coccidioides immitis.

Archives
2012
April (1)
March (1)
February (1)
2011
December (3)
October (1)
September (16)
July (1)
June (2)
May (2)
April (1)
March (3)
February (2)
2010
December (3)
November (2)
October (1)
September (1)
June (1)
March (1)
January (11)
2009
August (1)
July (1)